Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Assessment 2024

Hope for a strong and quick recovery from the COVID-19 induced U.S. recession became more uncertain with the dramatic and historic decline in Q2 2020 U.S. GDP. There are also economic signs that a full economic recovery to pre-pandemic levels is still elusive. Continued economic uncertainty remains. Further, while the resurgence of COVID-19 cases seen in many states this past June, especially in ...

The upcoming November 2020 presidential and congressional elections represent a key event for the pharma industry. Current industry focus is on COVID-19, the effects from public policy mandates on pharma business operations, resulting in recessionary effects on market access and affordability, and the search for effective vaccines and treatments. Yet, a Democratic Party election sweep by winning ...

The pharmaceutical industry has stepped up in a big way in search of vaccines and effective treatments for COVID-19. One reference cited at least 250 drugs and 95 vaccines under investigation related to COVID-19. The coronavirus pandemic has clearly shown the societal value of having a pharmaceutical industry with a robust capability to develop new medicines and to operate in an economic system ...

The shift to commercializing specialty medicines, where market performance will be predicated on the demonstration and delivery of scientific evidence, will mean the importance of intangible assets like intellectual property (IP) will be fundamental to future biopharmaceutical financial success. The global nature and internal structure of biopharmaceutical multinational corporations (MNCs) means ...

This white paper investigates the research framework to model the expected effects of the decline in health outcomes caused by a decrease in the quantity and quality of pharmaceutical utilization due to the economic effects of a deep and long recession. Four effects caused by a deep recession that will adversely affect the utilization of branded/biologic drugs, which, in turn, will cause a ...

This white paper looks at a simple but important research question – why do pharma companies have incentive compensation (IC) plans that cap their at-risk sales rep compensation? This paper provides reasons why such caps are not justified on both theoretical and empirical grounds, notes counterarguments to those who argue for IC caps, and offers two typical case studies that reveal both negative ...

The rapid spread of COVID 19 has resulted in pharma companies facing significant ramifications on their business, requiring a change in assumptions, thinking, and decisions going forward. One such critical area of effect from the pandemic is on incentive compensation (IC). Pharma company investment in the sales force is significant in both personnel and economic terms. Mandates on social ...

Real world evidence (RWE) has traditionally been leveraged to inform predominantly product development decisions, payer contracts, and health economic and outcome research (HEOR) studies. There is now an increased emphasis on leveraging RWE across a broader range of business functions given the industry shift towards specialty drugs and the treatment of rare diseases. Now with more outcomes-based ...

The outbreak of the coronavirus pandemic illustrates the inherent risks and uncertainties that are prevalent in the operation of complex and global business, as seen in the pharmaceutical industry. The coronavirus pandemic also illustrates the need for companies to have empirical systems in place to act quickly to mitigate the effects of such events when they do occur. This white paper provides a ...